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Introduction
Local excision of rectal tumors has long been performed. 
The transsphincteric and transcoccygeal approaches had 
been used for local excision, especially for high-lying rectal 
tumors. The transcoccygeal (Kraske) approach requires 
mobilization of posterior pelvic floor muscles away from 
the coccyx to expose the rectum and the transsphincteric 
(York-Mason) approach involves complete division of the 
anal sphincter. With the development of new technologies 
for endoluminal operation, the transsphincteric and 
transcoccygeal approaches are rarely used today. Transanal 
excision (TAE) was first described by Parks as an alternative 
endoluminal treatment for certain rectal tumors in 1970 (1). 
After 10 years, anorectal surgical procedures with the use 
of different endoscopic devices into the anal canal were 
introduced. Transanal endoscopic microsurgery (TEM) 
was first described by Buess et al. in 1984 (2). A few years 
later, a newer and simpler alternative transanal endoscopic 
operation (TEO), was introduced and widely implemented. 
Maeda et al. (3,4) proposed a new transanal local excision 
procedure, minimally invasive transanal surgery (MITAS), 
for excising a proximal tumor at more distal sites. Recently, 
transanal minimally invasive surgery (TAMIS) has become 
increasingly more popular. 
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Selecting the appropriate surgical approach to rectal 
tumors is important. The approach must balance successful 
tumor eradication with functional implications for the 
patient. Owing to the significant morbidity and alterations 
in quality of life associated with rectal surgery (low anterior 
resection and abdominoperineal resection), a lot of time 
and research have been devoted to transanal approaches for 
rectal tumors. Several retrospective studies since the 1970s 
reported that TAE of early tumors with negative margins 
may provide similar outcomes those of radical resection (5). 
Since then, there had been many studies assessing the role 
of TAE of rectal cancer (6). Thereafter, the use of TAE had 
increased to 17.1% for T1 lesions and 11% for T2 lesions 
from 1989 to 2003 (7). 
During the recent decades, total mesorectal excision 
(TME) has become the standard technique for the surgical 
treatment of rectal cancer (8). Nowadays, transanal TME 
(taTME) has been proposed as a new option in cases for 
which laparoscopic transabdominal TME (laTME) is 
difficult. TaTME is not a completely novel concept and it 
has benefited from previous experience of transabdominal-
transanal (TATA) operations, TEM, TAMIS and natural 
orifice transluminal endoscopic surgery (NOTES) (9-11). 
Since the first taTME resection assisted with laparoscopy 
was reported in 2010 (12), taTME has shown promising 
results with regard to pathological quality and short- and 
mid-term outcomes (13-15).
Indication for TAE to rectal tumors
Local excision of rectal tumors has been advocated for 
premalignant lesions and used as definitive treatment 
for early rectal cancers in select groups without adverse 
prognostic features (16). Atypical rectal tumors such as 
neuroendocrine tumors and gastrointestinal stromal tumors 
are also usually approached through the transanal. 
Local excision is suitable for Tis (carcinoma in situ) 
or T1 cancers with a favorable histology. The criteria 
for local treatment include T0 or Tis lesions; low-
risk differentiated (well-to-moderately) T1 cancer; 
absence of lymphatic, vascular, or perineural invasion; 
and tumors ≤3 cm in diameter occupying ≤40% of the 
circumference of the rectal lumen. These principles 
apply to all local excision techniques. However, with the 
development of the technique and increased experience of 
surgeons, the indications have expanded. These technical 
approaches have extended beyond local excision, with 
the development of taTME being the most important in 
recent years. Additionally, for accurate patient selection, 
routine preoperative cardiopulmonary assessment, 
physical examination with digital rectal examination, fecal 
incontinence test, endoscopy, trans-rectal ultrasound 
(TRUS), and in case of malignancy; complete staging 
workup with pelvic magnetic resonance imaging and 
abdominal computed tomography, are recommended. 
For determining local excision, local T staging should be 
accurate. TRUS allows predicting early T1 lesions that 
might be suitable for local excision. Hildebrandt et al. (17) 
proposed a preoperative tumor staging system based on 
ultrasonic determination of the infiltrative depth of tumors, 
so-called uTNM, and this technique contribute to a more 
accurate determination of the depth of invasion with 
classification of the rectal wall layer.
Techniques for the transanal approach
 Conventional TAE.
 MITAS.
 Transanal endoscopic surgery (TES).
 TEM;
 TEO;
 TAMIS;
 taTME.
TAE
TAE has been the mainstay of treatment for many years. 
TAE is a simple method that can be easily performed if 
the tumor is located in the anal canal and easily accessible 
under adequate exposure of the anal canal. There is no 
need for additional equipment, and it can be performed in 
the outpatient department. An additional benefit to this 
approach is the minimal, if any, compromise of anorectal 
and urogenital function. These factors make TAE the most 
common method of local excision (18). 
Conventional TAE is often limited to tumors ≤4 cm 
in diameter that lie within 6–8 cm of the anal verge (16). 
Lesions in the middle and upper rectum are usually 
inaccessible with TAE because of their distance from the anal 
verge, and attempted excisions are hampered by inadequate 
surgical exposure, confinement of the operating field, 
and uncertainty of a clear surgical resection margin (19).
Patients should undergo preoperative assessment 
including digital rectal examination and rigid sigmoidoscopy 
to confirm location and mobility. Patients receive a cleansing 
enema the day before the operation; prophylaxis with 
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antibiotics and antithrombotics is usually recommended. 
After the induction of local, regional, or general anesthesia, 
the patient is placed in position. Some authors additionally 
propose pudendal nerve block for sphincter relaxation. The 
positioning of the patient is dependent on the preference of 
the surgeon; however, the orientation of the lesion is usually 
the deciding factor, with preference taken to operating 
downward. Most operations are performed with the patient 
in the prone jackknife position; however, some posteriorly 
located lesions may be better approached with the lithotomy 
position. The perianal area is exposed by taping the buttocks 
apart; the lesion is exposed with direct vision by using a 
Hill Ferguson, Park, or Barr retractor. Traction sutures can 
be placed distal to the lesion to improve visualization. The 
calculated excision margin (10 mm) is typically marked by 
using electrocautery in a circumferential pattern around 
the lesion. The specimen must be carefully taken so as not 
to manipulate the lesion or handle it with instruments. 
After a full thickness excision of the lesion, the specimen 
is oriented on a needle board and sent to the pathology 
laboratory. After irrigation, the defect can be either left 
open or closed transversely with absorbable sutures. If the 
lesion is posterior to the rectum and above the puborectalis 
muscle, the defect is closed with absorbable sutures. 
In case of anteriorly located lesions, repair should be 
conducted to avoid injury of adjacent structures, such as the 
prostate, urethra, or vagina. At the end of the procedure, 
a proctoscopic examination is essential to confirm that the 
rectal lumen was not inadvertently closed or narrowed.
Complications associated with TAE include urinary 
retention, urinary tract infection, infections of the 
perirectal and ischiorectal space, fecal impactions, and 
delayed hemorrhage. Nevertheless, the incidences of these 
complications and mortality are very low. TAE has several 
limitations. In general, this approach is technically difficult 
with higher lesions owing to poor visualization. More 
important, visualization during TAE can be suboptimal, 
which can affect the quality of an oncologic resection 
margin. Concerns have also been raised about the high rates 
of tumor fragmentation and recurrence with TAE. The 
high rates of recurrence are likely due to rates of margin 
positivity that exceed 10% in even the most experienced 
and expert case series (6,18). Patients treated with TAE 
compared with those treated with radical surgery for 
T1 rectal cancer had a significantly higher 5-year local 
recurrence rate (12% vs. 6%) and lower 5-year survival 
rate (70% vs. 80%) and 5-year disease-free rate (64% vs. 
77%) (20).
MITAS
A new transanal local excision procedure, MITAS, has been 
developed with a specially designed anal retractor connected 
to the Octopus retractor holder, a stapler device, and several 
newly developed techniques to excise a proximal tumor at a 
more distal site (21). 
Operation was usually performed under spinal anesthesia 
with the patient in lithotomy or jackknife position, 
according to the site of tumor (4). The procedure consists 
of inserting into the rectum an originally designed E- or 
F-type anal retractor [a modified K-type anal retractor (22); 
Yufu Itonaga Co Ltd.] connected to the Octopus retractor 
holder, long type, 22 inches (Mednosbro AG).
To enable excision of a proximal tumor at a more 
accessible site, shortening or roll-in technique, intussusception, 
or invagination technique with retraction stitches is used. 
The retractor is inserted into the anus and rolled to pull 
the rectum in and permit easy access to the tumor in the 
proximal rectum (3). When the tumor is still beyond the 
surgical field, the retractor is opened and fixed and two 
Babcock forceps are used to pull the tumor gradually (21). 
Retraction stitches are passed under the tumor, from one 
side to the other with a minimum macroscopic margin 
of 5 mm from the boundary of the tumor to the adjacent 
normal mucosa by a 36-mm-long atraumatic needle with 
absorbable 1-0 thread, enough to retract the tumor fully 
and pull the rectum down. ENDO GIA (Tyco Co Ltd.) is 
used for excision and anastomosis while fully retracting the 
rectum with retraction stitches distally. Application of a 
stapler is usually done transversely, but oblique application 
is sometimes needed because of the difficult angle in the 
rectum or size of the tumor. 
TES
TEM
Gerhard Buess of Germany pioneered TEM (Richard 
Wolf, Germany) in the early 1980s as a minimally invasive 
technique allowing the resection of adenomas and early 
rectal carcinomas unsuitable for local or colonoscopy 
excision, which would otherwise require major surgery (23). 
This method was basically designed from the idea of 
laparoscopic surgical techniques so-called because it is a 
minimally invasive technique and has proved to be useful 
for treating lesions in the mid or upper rectum. The main 
indications for TEM are rectal tumors that are out of reach 
for TAE and are unsuitable for endoscopic removal (24). 
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In addition, this technique can even be extended to lesions 
in the low sigmoid colon, with success reported up to 
20 cm from the anal verge (25). Since its development, 
TEM has been also used for a variety of other rectal 
pathologies including neuroendocrine tumors, rectal 
prolapse, early stage carcinomas, and palliative resection of 
rectal cancers (26).
The orientation of the lesion is usually the deciding 
factor for the positioning. The lesion needs to be 
situated at the 180 degree angle of the scope view. For 
a posterior lesion, the patient is placed in a lithotomy 
position. For an anterior lesion, the patient is placed in 
the prone jackknife position. The operative technique 
for TEM involves three main components: a rigid 
operating rectoscope, a laparoscopic camera, and modified 
laparoscopic instruments. The operating rectoscope is 
typically 4 cm in diameter and varies from 12 to 20 cm in 
length. The rectoscope maintains an airtight seal at the 
anus once inserted in the rectum, and is held in place by 
the obligate articulating arm, which fixes the rectoscope 
to the operating table. The rectoscope has a port for the 
inflow of CO2 for the pneumorectum, and an outflow for 
smoke evacuation during cauterization. The faceplate on 
the rectoscope has four ports through which a stereotactic 
telescope with connection to a three-dimensional video 
system and three modified laparoscopic instruments are 
connected to facilitate dissection and suturing (26). While 
the instruments are specialized, the operative steps are 
otherwise no different than for TAE. The lesion is then 
centered in the scope view. By using scissors, cautery, and 
graspers, a dotted line is burned around the target lesion 
with a 10-mm margin. Care must be taken to avoid trauma 
to and fragmentation of the specimen. After homeostasis is 
obtained, the defect is closed with absorbable full-thickness 
sutures in a transverse line. The defect can be left open to 
heal secondarily if the defect is posterior and surrounded by 
mesorectal fat. An anterior defect must be closed; closure is 
facilitated by placing a central stay suture and sewing from 
each corner to avoid tension on the suture line. 
The limitation of TEM is that the equipment is designed 
to operate from the top-down; thus, the lesion must 
be oriented toward the floor to be compatible with the 
equipment. This means that the patient’s positioning is 
dependent on the tumor location, and sometimes specialized 
split-leg operating tables are necessary to resect anterior 
tumors requiring the prone jackknife position. Distal 
lesions near the sphincter are difficult to excise with TEM 
owing to the configuration of the equipment and inability 
to maintain insufflations of CO2 to distend the rectum. This 
is the reason why TAE is easier to use for low-lying lesions. 
Other limitations to TEM focus on specialized equipment, 
which have a steep learning curve and high associated costs 
for the hospital (27,28). 
TEO
A few years later a cheaper alternative was introduced 
compared with TEM. The TEO (Karl Storz, Germany), 
which was a newer and simpler system, has become widely 
implemented. Indication of TEO is similar to TEM. 
TEO platform was performed in a lithotomy position 
using a 30° forward-oblique telescope, adequate adjustment 
of the rectoscope, and curved laparoscopic operating 
instruments. TEO procedure was carried out under general 
anesthesia. After installation of the holding system, the anus 
was gently dilated, and the operating rectoscope (7.5 or 
15 cm long, 4 cm in diameter) with obturator was inserted 
in the rectum with copious lubricant and fastened to the 
support arm attached to the operating table. The working 
attachment used with the rectoscope had two channels 
for instruments of 5 mm and one channel for instruments 
up to 12 mm. After achieving the pneumorectum with 
insufflations of CO2 to 12 mmHg or more, a high definition 
(HD) 5-mm diameter endoscope with fiber-optic light 
transmission and 30° angled view was inserted through a 
5-mm endoscope channel and the rectoscope was adjusted 
to achieve the best position for procedures (Figure 1A). 
Except the instruments are specialized, the operative steps 
are otherwise no different than those for TEM.
Similar to TEM, lesions near the anal verge are difficult 
to excise with the TEO. Standard laparoscopic instruments, 
equipment, and set up costs are lower, potentially opening 
the technique to any surgeon with previous laparoscopic 
experience. Hur et al. (29) performed initial experience of 
TEO and reported the mean operative time was 85 minutes, 
and the mean postoperative hospital stay was 4.5 days, a 
positive resection margin was documented for 9% patients. 
Furthermore, they demonstrated that according to the 
cumulative sum analysis, the operation time and hospital 
stay significantly decreased after 17 case experiences (29). 
Several studies have compared TEO with TEM for 
benign and malignant lesions and have shown satisfactory 
outcomes (30,31).
TAMIS
In recent years, TAMIS has become increasingly more 
popular. Reported by Atallah et al. (32) in 2010, the 
Annals of Laparoscopic and Endoscopic Surgery, 2016 Page 5 of 11
© Annals of Laparoscopic and Endoscopic Surgery. All rights reserved. Ann Laparosc Endosc Surg 2016;1:35ales.amegroups.com
technique stems from the use of a single port initially 
designed for abdominal surgery. Since the inception of 
TAMIS, at least 390 procedures were reported worldwide 
from 2010 to 2013 (33). This technique uses a single, 
disposable, multichannel port inserted into the anus as 
opposed to the rigid operating rectoscope. Currently in 
the United States, two ports are approved for TAMIS by 
the Food and Drug Administration: single-incision assisted 
laparoscopic surgery port (Covidien, USA; Figure 1B) 
and GelPOINT Path Transanal Access Platform (Applied 
Medical, USA; Figure 1C). 
The indications of TAMIS are the same as those of 
other TES. The main benefits of TAMIS are the relative 
ease of use and low cost, owing to the use of conventional 
laparoscopic instruments, including a laparoscopic camera, 
graspers, energy sources, and a standard laparoscopic CO2 
insufflator. It is ideal for lesions at 8–12 cm from the anal 
verge; however, it has been successfully performed in the 
lower and mid rectum (34). Distal lesions are covered by 
the transanal port, and excision of very proximal lesions can 
cause entry into the peritoneal cavity. 
Mechanical bowel preparation or enema, antibiotics 
and antithrombotic prophylaxis are usually recommended. 
Anesthesia may be general or spinal. Lee et al. (35) have 
reported a series of 25 TAMIS procedures in which spinal 
anesthesia was used. In TAMIS, most lesions can be excised 
with a lithotomy position. However, we still recommend 
the prone position for the patients with large anterior 
lesions, especially if the distance from the anal verge is in 
a range in which there might be a risk of perforating the 
peritoneum. After the patient is positioned and the port is 
placed, pneumorectum is achieved with the standard CO2 
insufflator, with pressures ranging from 15 to 25 mmHg. 
Several different cameras can be employed, including those 
with a flexible tip. One common practice is to use the 5-mm, 
30-degree bariatric camera with a right-angle light cord 
Figure 1 Procedure and position for TEO (A), single-incision assisted laparoscopic surgery port (B), GelPOINT path transanal access 
platform (C), glove port for robotic TAMIS (D). TEO, transanal endoscopic operation; TAMIS, transanal minimally invasive surgery.
A
C
B
D
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adaptor. Conventional graspers, scissors, and electrocautery 
devices are employed, along with ultrasonic or bipolar 
energy devices as needed. Owing to the technical challenges 
of suturing in this confined working space, many techniques 
similar to TEM have been employed, including the use 
of clips and beads, barbed suture, and specialized suturing 
devices. 
When compared with other platforms, TAMIS has 
several advantages. Devices that are used for TAMIS are 
more pliable than the 40-mm rigid scope used for TEM, 
and possibly lead to less impairment of sphincter function; 
the set-up time is significantly lower for TAMIS. Use of 
regular conventional laparoscopic instruments, as opposed 
to the fixed eyepiece of the TEM rectoscope, enables 
advancing the scope into the proximal rectum to look 
beyond the tumor. TAMIS is easily learned by surgeons 
because of its simplicity and similarity with conventional 
laparoscopic surgery, and it is a cost effective alternative 
to TEM (32). For some authors, the introduction of the 
TAMIS port into the anal canal makes it more complex 
than TEM or TEO (36). A disadvantage of TAMIS is 
that the rectoscope cannot be mobilized at the site of the 
lesion; rectal lesions behind a rectal haustral valve may be 
more difficult to access and remove. The longer channels 
associated with TEM and TEO equipment facilitates 
intraluminal rectal retraction. Moreover, an assistant is 
required to hold and manipulate the laparoscope during the 
TAMIS procedure.
The authors who introduced TAMIS went on to describe 
the use of a robotic platform for TAMIS in a cadaveric 
model in 2011 (37), and then extended that robotic TAMIS 
platform to live patients in 2012 (38). Since then, its use in 
in humans has been described with both the GelPOINT 
Path platform (Applied Medical, USA) and a glove port 
(Figure 1D) (39). 
The authors suggested that the transanal glove port 
facilitated the robotic setup, enabling flexibility and 
allowing docking of the cannulas away from the limited 
perianal workspace (40). Furthermore, the glove port 
provided a wider axis of movement for instruments inside 
the rectum, or allowed them to be easily rotated and/or 
crossed. Although robotic TAMIS has been shown to be 
feasible, this technique is still relatively new, and more 
studies are necessary before to widespread adoption.
Postoperative complication of TES
Regardless of procedures, the morbidity and mortality 
are lower than for radical surgery. Operative mortality 
is less than 0.5% and morbidity ranges from 4% to 30% 
in large series, depending on the inclusion of minor 
complications. The most frequent complications include 
acute urinary retention, bleeding requiring reoperation, 
abdominal perforation and recto-vaginal fistula (41). Kumar 
et al. (42) found that complications correlate with tumors 
located laterally and more than 8 cm from the anal verge. 
Pelvic sepsis, which occurs in about 3% of cases, is more 
common in lesions within 2 cm of the dentate line. The 
conversion rate to TAE is around 5%, and the main reason 
for conversion is technical difficulties (24,26). Peritoneal 
perforation, which was thought to represent a complication 
requiring conversion to laparotomy, can usually be salvaged 
with TES for experienced surgeons (43,44). A multicenter 
study by Baatrup et al. (45), performed by using database 
of 888 TEM procedures, found 22 perforations in the 
peritoneal cavity. They reported no association with major 
short term complications or adverse long-term oncological 
outcomes (45).
Outcomes of TES
Radical surgery with TME is still the treatment of choice 
for rectal cancer, offering patients the best results in terms 
of local recurrence and survival (46). However, TME is 
associated with significant mortality and morbidity (47). 
According to the experience in the last decades, TEM and 
TEO have been accepted as effective treatments in selected 
patients with early rectal cancer, with similar oncologic 
outcomes to and better functional effects than those of 
radical surgery (48,49). Recently, TAMIS has been proposed 
as an alternative technique; however, the experience with 
this approach for rectal cancer is still limited because of 
short follow-up (27,33,50-55).
TEM has a lower positive resection margin rate than 
TAE, with less fragmented specimens and better oncologic 
outcomes (56,57). Elmessiry et al. (50) showed that TAE was 
an independent predictor of local recurrence compared with 
TEM. The rate of reported positive resection margin in the 
surgical specimen in TAMIS was 4.4–6% (27,33,54), similar 
to those obtained with TEM, and seems to be related with 
the T stage (26,58,59). Some studies have compared TEM 
with radical surgery in early rectal cancer, showing similar 
results in terms of local recurrence and survival (60,61). In a 
meta-analysis, Winde et al. (62) demonstrated that the rate 
of local recurrence was higher with TEM (12% vs. 0.5%); 
however, no difference in survival was found. 
TES seems to be a reasonable alternative to radical 
surgery in patients with low-risk rectal cancer (26,41,47, 
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48,52,61,63,64) with local recurrence rates ranging from 0% 
to 39%. These wide differences in range can be explained 
by the heterogeneity of cases, different selection criteria, 
risk characteristics, and surgical techniques; however, most 
local recurrence rates are under 10% (24,26,60,62,65-70). 
TES alone is not appropriate for patients with T2 or worse 
tumors, considering that the risk of local recurrence varies 
between 9.5% and 47% (24,26,47,52,58-61,64,68-72). 
However, even in these studies there are considerable 
differences between low- and high-risk cancers (73). TES 
may be performed on patients with high-risk T1 or T2–3 
tumors with poor life expectancy and severe morbidity, 
or those unfit for major surgery, or simply as palliative 
treatment in case of disseminated disease (47,61,63). 
Salvage surgery for recurrence after TES demonstrated 
disappointing oncologic outcomes; the stage is usually 
more advanced than in primary lesions and may require 
multivisceral resection and an ostomy in up to 43% of 
cases. Survival is seriously compromised, with a 5-year 
survival ranging from 43% to 68%, dropping to 29% in 
patients with unfavorable histology (63,68,74). In contrast, 
Levic et al. did not find any difference in outcome between 
patients with rectal cancer undergoing immediate salvage 
TME after TEM and those undergoing primary TME (75). 
Despite contrasting conclusions, all authors warned that 
perforations into the original operating field during 
subsequent TME can occur owing to fibrotic changes to the 
bowel wall, which might allow microscopic tumor spillage.
Future perspectives
Several new techniques and approaches are still under 
investigation, currently in preclinical or experimental stages, 
such as transanal natural orifice transluminal endoscopic 
surgery (NOTES), taTME, and robotic-TES (26,51,76). 
TES platforms seem to be safe for both transanal NOTES 
and taTME (77,78). Robotic technology can lower the 
difficulty inherent in TES platforms (79). However, clinical 
trials are necessary for full evaluation of these techniques.
taTME
The latest development in transanal approaches is taTME. 
Transanal TME was introduced in 2010 with the aim to cope 
with all these limits and improve the quality of mesorectal 
dissection even in the most challenging cases (11). 
Dissection of the distal rectum according to TME 
principles may be somewhat cumbersome in cases of narrow 
pelvis, bulging tumors, and obese patients. In adequate 
exposure and loss of the good plane of dissection require 
finding another alternative treatment approach. During the 
last decade, transanal approaches have been extensively used 
to overcome the inherent shortcomings of laTME (69,77). 
Among these emerging transanal techniques, taTME is a 
new minimally invasive procedure with the essential aim 
of improving oncological treatment quality and avoiding 
pelvic nerve injury in patients with mid or low rectal cancer. 
Given the encouraging outcomes of systematic investigation 
of taTME for patients with rectal cancer (80,81), taTME 
may be optimized as a surgical approach for rectal cancer. 
In comparison with conventional laTME, taTME defines 
the distal resection margin more precisely, with better 
visualization of the distal rectum, and allows the surgeon to 
perform deep pelvic dissection without the need for difficult 
retraction (82). However, the benefits of taTME compared 
with laTME must be confirmed before conducting 
multicenter randomized controlled trials (RCTs) and 
unifying taTME procedures. According to a meta-analysis 
study, the percentage of patients with complete mesorectum 
was 83.4% in the taTME group and 73.4% in the laTME 
group (83). In addition, achievement of complete plus 
near complete mesorectum was also greater in the taTME 
group (95.3% vs. 88.2%) (83). Hence, for patients with mid 
or low rectal cancer, taTME may achieve a complete or 
near complete resection of the mesorectum relative easily, 
compared with laTME. However, whether a higher quality 
of mesorectal resection will result in good survival remains 
unknown. Safety is always the most important issue for a 
new technique. The meta-analysis indicated a comparable 
rate of intraoperative complications and a significantly 
lower incidence of postoperative complications in the 
taTME group than in the laTME group (83). 
As the new surgical technique of taTME is adopted 
increasingly by surgeons, the patient selection criteria 
will be crucial and will continue to inspire debate. Of 
note, the protocol published recently for a multicenter 
RCT comparing taTME with laTME (COLOR III) 
has formulated strict criteria for patient selection (84). 
According to the selection criteria of this protocol, T3 
tumors with margins <1 mm to the endopelvic fascia, 
tumors with ingrowth in the internal sphincter or levator 
ani muscle, and all T4 tumors staged before preoperative 
therapy were excluded (84). However, the nature of the 
surgical candidates best suited to taTME treatment requires 
further studies.
In a matched case-control study from Taiwan, Chen 
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et al. (85) demonstrated that compared with laTME, 
taTME not only achieves identical circumferential margin 
status without compromising other operative and quality 
parameters but also benefits patients by achieving a longer 
distal margin. Additionally, Denost et al. (86) performed 
a randomized trial in France, and reported that the rate 
of positive circumferential resection margin decreased 
significantly after taTME compared with abdominal low 
rectal dissection (4% vs. 18%; P=0.025). Currently, RCTs 
examining taTME are under way; the COLOR III study has 
been designed to compare taTME versus laTME for mid 
and low rectal cancer. TaTME is expected to be superior to 
laTME in terms of clear circumferential resection margins 
in case of mid and low rectal carcinomas (84). Although 
taTME is another new technique with great promise, the 
supporting data are preliminary, and further studies with 
larger cohorts of patients are needed to evaluate long term 
functional and oncological outcomes.
Conclusions
There have been significant advances in the transanal 
approach in the last 30 years. Appropriate patient selection 
is the key for good outcomes. These techniques have 
enabled mid and upper rectal lesion and sphincter salvage, 
leading to a better quality of life. From the point of view 
of technical advancement, it would be better to adopt 
this technique as a treatment option, and prospectively 
randomized comparison clinical trials should be conducted. 
When we are planning treatment for patients with early 
rectal cancer, the risk of local recurrence must be balanced 
with the quality of life. Nowadays, transanal approaches 
including taTME should be considered as good options for 
the treatment of rectal cancer because these techniques are 
definitely useful in selected patients.
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